Phaseline

Targets › SFTPB

SFTPB (Pulmonary surfactant-associated protein B): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Neurology; next expected readout Jul 2028.

Pulmonary surfactant-associated proteins promote alveolar stability by lowering the surface tension at the air-liquid interface in the peripheral air spaces. SP-B increases the collapse pressure of palmitic acid to nearly 70 millinewtons per meter. (UniProt, P07988)

Open in Phaseline: the race on SFTPB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Medical University of GrazPoractant alfa (Curosurf®)
Pulmonary surfactant replacement therapy
SFTPB, SFTPC, SFTPA1, SFTPA2Phase 4Neonates and Preterm InfantsJul 2028

Conditions

Neonates and Preterm Infants (1)

Modalities

small molecule (1)

Companies

Medical University of Graz (1)

Related targets

SFTPC (1) SFTPA1 (1) SFTPA2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.